Avalo Therapeutics Inc expected to post a loss of $1.39 a share - Earnings Preview

Avalo Therapeutics

09/05/2025 17:12

Avalo Therapeutics Inc AVTX.OQ AVTX.O is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Avalo Therapeutics Inc is for a loss of $1.39 per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 72.4% in the last three months. ​

Wall Street's median 12-month price target for Avalo Therapeutics Inc is $30.00​, above​ its last closing price of $4.35. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.25
-0.39
-7.95
Missed
-1,929.8
Sep. 30 2024
-1.10
-1.19
-1.25
Missed
-5
Jun. 30 2024
-6.70
-6.70
-14.07
Missed
-110​
Mar. 31 2024
-1.18
-1.18
-1.41 hundred
Missed
-11,849.2
​​Dec. 31 2023
-4.80
-1.16 hundred
Missed
-2,321.1
Sep. 30 2023
-2.64 hundred
-26.40
Beat
90​
Jun. 30 2023
-1.80 hundred
-1.92 hundred
-1.42 hundred
Beat
26.3
Mar. 31 2023
-2.33 hundred
-2.33 hundred
-2.04 hundred
Beat
12.4

This summary was machine generated May 9 at 16:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)